Immatics N.V. Updates IMA203CD8 Trial Data
Ticker: IMTX · Form: 6-K · Filed: Dec 11, 2025 · CIK: 1809196
Sentiment: neutral
Topics: clinical-trial-update, cell-therapy, oncology
TL;DR
Immatics dropped new solid tumor cell therapy data from its Phase 1a trial, showing results from 78 patients.
AI Summary
On December 11, 2025, Immatics N.V. released updated Phase 1a clinical trial data for its PRAME cell therapy, IMA203CD8. The data, with a cutoff of October 27, 2025, included 78 heavily pre-treated patients with solid tumors, who had received a median of three prior systemic treatments.
Why It Matters
This update provides crucial insights into the efficacy and safety of Immatics' novel cell therapy for solid tumors, potentially impacting future treatment options for cancer patients.
Risk Assessment
Risk Level: medium — Clinical trial data updates for novel therapies carry inherent risks related to efficacy, safety, and future development path.
Key Numbers
- 78 — Patients (Number of heavily pre-treated patients with solid tumors evaluated in the Phase 1a trial.)
- 3 — Prior Treatments (Median number of prior systemic treatments received by the patients.)
Key Players & Entities
- Immatics N.V. (company) — Filer of the report and developer of the therapy
- IMA203CD8 (drug) — Second-generation PRAME cell therapy being evaluated
- October 27, 2025 (date) — Data cutoff date for the clinical trial results
- December 11, 2025 (date) — Date of the Form 6-K filing
- 78 (number) — Number of heavily pre-treated patients included in the data
FAQ
What specific dose escalation data was updated for IMA203CD8?
The filing indicates updated dose escalation data was provided, but the specific details of this data are not elaborated within the provided text.
What types of solid tumors were included in the trial?
The filing states the trial evaluated patients with 'solid tumors' but does not specify the exact types of solid tumors.
What was the primary endpoint of this Phase 1a trial?
The provided text does not explicitly state the primary endpoint of the Phase 1a clinical trial.
What is the significance of 'heavily pre-treated' patients in this context?
This designation means the patients have undergone multiple prior lines of systemic treatment, indicating a high unmet medical need for effective therapies.
When will further data from this trial be released?
The filing does not provide information on the timeline for future data releases.
Filing Stats: 1,595 words · 6 min read · ~5 pages · Grade level 13.2 · Accepted 2025-12-11 07:10:17
Filing Documents
- dp238568_6k.htm (6-K) — 27KB
- dp238568_ex9901.htm (EX-99.1) — 37KB
- dp238568_ex9902.htm (EX-99.2) — 41KB
- dp238568_ex9903.htm (EX-99.3) — 114KB
- image_001.jpg (GRAPHIC) — 14KB
- image_002.jpg (GRAPHIC) — 31KB
- image_003.jpg (GRAPHIC) — 40KB
- image_004.jpg (GRAPHIC) — 4KB
- image_005.jpg (GRAPHIC) — 69KB
- image_006.jpg (GRAPHIC) — 150KB
- image_007.jpg (GRAPHIC) — 158KB
- image_008.jpg (GRAPHIC) — 235KB
- image_009.jpg (GRAPHIC) — 218KB
- image_010.jpg (GRAPHIC) — 250KB
- image_011.jpg (GRAPHIC) — 112KB
- image_012.jpg (GRAPHIC) — 145KB
- image_013.jpg (GRAPHIC) — 86KB
- image_014.jpg (GRAPHIC) — 140KB
- image_015.jpg (GRAPHIC) — 92KB
- image_016.jpg (GRAPHIC) — 84KB
- image_017.jpg (GRAPHIC) — 130KB
- image_018.jpg (GRAPHIC) — 107KB
- image_019.jpg (GRAPHIC) — 58KB
- image_020.jpg (GRAPHIC) — 133KB
- image_021.jpg (GRAPHIC) — 89KB
- image_022.jpg (GRAPHIC) — 131KB
- image_023.jpg (GRAPHIC) — 64KB
- image_024.jpg (GRAPHIC) — 151KB
- image_025.jpg (GRAPHIC) — 93KB
- image_026.jpg (GRAPHIC) — 93KB
- image_027.jpg (GRAPHIC) — 88KB
- image_028.jpg (GRAPHIC) — 90KB
- image_029.jpg (GRAPHIC) — 93KB
- image_030.jpg (GRAPHIC) — 85KB
- image_031.jpg (GRAPHIC) — 47KB
- image_032.jpg (GRAPHIC) — 75KB
- image_033.jpg (GRAPHIC) — 111KB
- image_034.jpg (GRAPHIC) — 93KB
- image_035.jpg (GRAPHIC) — 91KB
- image_036.jpg (GRAPHIC) — 94KB
- image_037.jpg (GRAPHIC) — 95KB
- image_038.jpg (GRAPHIC) — 90KB
- image_039.jpg (GRAPHIC) — 70KB
- image_040.jpg (GRAPHIC) — 112KB
- image_041.jpg (GRAPHIC) — 79KB
- image_042.jpg (GRAPHIC) — 84KB
- image_043.jpg (GRAPHIC) — 94KB
- image_044.jpg (GRAPHIC) — 46KB
- image_045.jpg (GRAPHIC) — 91KB
- image_046.jpg (GRAPHIC) — 107KB
- image_047.jpg (GRAPHIC) — 78KB
- image_048.jpg (GRAPHIC) — 90KB
- image_049.jpg (GRAPHIC) — 115KB
- image_050.jpg (GRAPHIC) — 92KB
- image_051.jpg (GRAPHIC) — 88KB
- image_052.jpg (GRAPHIC) — 86KB
- image_053.jpg (GRAPHIC) — 45KB
- image_054.jpg (GRAPHIC) — 125KB
- image_055.jpg (GRAPHIC) — 88KB
- image_056.jpg (GRAPHIC) — 94KB
- image_057.jpg (GRAPHIC) — 83KB
- image_058.jpg (GRAPHIC) — 107KB
- image_059.jpg (GRAPHIC) — 76KB
- image_060.jpg (GRAPHIC) — 81KB
- image_061.jpg (GRAPHIC) — 113KB
- image_062.jpg (GRAPHIC) — 100KB
- image_063.jpg (GRAPHIC) — 91KB
- image_064.jpg (GRAPHIC) — 44KB
- image_065.jpg (GRAPHIC) — 97KB
- image_066.jpg (GRAPHIC) — 148KB
- image_067.jpg (GRAPHIC) — 95KB
- image_068.jpg (GRAPHIC) — 334KB
- image_069.jpg (GRAPHIC) — 141KB
- image_070.jpg (GRAPHIC) — 66KB
- image_071.jpg (GRAPHIC) — 295KB
- image_072.jpg (GRAPHIC) — 281KB
- image_073.jpg (GRAPHIC) — 105KB
- image_074.jpg (GRAPHIC) — 208KB
- image_075.jpg (GRAPHIC) — 256KB
- image_076.jpg (GRAPHIC) — 68KB
- 0000950103-25-015984.txt ( ) — 11662KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: December 11, 2025 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer